Medical School
University of Pittsburgh
Residency
Thomas Jefferson University Hospital
Fellowship
Thomas Jefferson University Hospital
Walter Kraft, MD
Professor
Director, Division of Clinical Pharmacology
Director, Office of Human Research Protection
Director, Clinical Research Unit
Contact Information
Academic Office
132 South 10th Street
1170 Main Building
Philadelphia, PA 19107
215-955-9077
215-955-5681 fax
Professor
Director, Division of Clinical Pharmacology
Director, Office of Human Research Protection
Director, Clinical Research Unit
Education
Publications
- Optimal Drug, Optimal Dose, or Both in the Pharmacological Treatment of Neonatal Opioid Withdrawal Syndrome?
- Pharmacodynamics of Aspirin Through Gestation: Predictors of Aspirin Response and Association With Pregnancy Outcome, a Prospective Cohort Study
- Bayesian Population Pharmacokinetic Modeling of Ondansetron for Neonatal Opioid Withdrawal Syndrome
- The role of 5-HT modulation in opioid withdrawal and neonatal opioid withdrawal syndrome: mechanisms and potential serotonergic targets
- Assessment of pharmacokinetics and tolerability following single-dose administration of molnupiravir in participants with hepatic or renal impairment
Board Certification
Clinical Pharmacology
Internal Medicine
Research Interests
- Phase one clinical trials
- Treatment of neonatal abstinence syndrome
- Clinical Pharmacology
Clinical Interests
- Anticoagulation
- Hospital-based vascular medicine consultation
Industrial Relevance
Dr. Kraft has expertise in the clinical, regulatory, and managerial aspects of Phase 1 drug development.
Biography
Dr. Kraft is an internist and a clinical pharmacologist. He is the director of the Thomas Jefferson University Clinical Research Unit. The CRU, located within the Thomas Jefferson University Hospital, specializes in Phase 1 trials in federally funded and industry sponsored investigations. Populations have included both heathy volunteers, as well as adult and pediatric patients with cancer, Hepatitis C, end stage renal disease, epilepsy, hemophilia, and migraine. He has an interest in the development of novel therapeutics in the neonatal abstinence syndrome (NAS). He is co-PI on the NIGMS funded fellowship program in Clinical Pharmacology at Jefferson. He is director of the Jefferson Office of Human Research, which oversees all human subjects’ protection for the Jefferson enterprise. He had held national leadership in a number of professional organizations including treasurer of American Society for Clinical Pharmacology and Therapeutics, and board membership on American Board of Clinical Pharmacology. He currently serves on the FDA advisory committee for Clinical Pharmacology. Lastly, he maintains a clinical practice in vascular medicine and the treatment of complex venous and arterial thrombotic diseases.